Profound Medical Corp. — Form 8-K
Filed July 24, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Profound Medical announced positive interim data from the CAPTAIN Level 1 randomized controlled trial comparing its TULSA-PRO system to robotic radical prostatectomy for intermediate-risk prostate cancer (Gleason 7). At 1 month, TULSA patients showed no median penile length change versus 0.65 cm reduction in robotic RP (p<0.001); TULSA previously demonstrated statistically significant superiority in erectile function and urinary continence preservation at 6 months. The trial enrolled 211 patients across 23 sites by August 2025, exceeding the planned 201-patient target.
Why this rating
Clinical trial data supporting TULSA differentiation in quality-of-life outcomes is meaningful for ~$152M company; addresses competitive vulnerability but penile length is secondary endpoint, not primary efficacy/safety measure.
See more from July 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.